Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa
- PMID: 31904819
- DOI: 10.1093/cid/ciaa003
Clinical Efficacy of Ceftolozane-Tazobactam Versus Other Active Agents for the Treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa
Comment in
-
Reply to Vena et al.Clin Infect Dis. 2020 Oct 23;71(7):1801-1802. doi: 10.1093/cid/ciaa004. Clin Infect Dis. 2020. PMID: 31904808 No abstract available.
Comment on
-
Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa.Clin Infect Dis. 2020 Jul 11;71(2):304-310. doi: 10.1093/cid/ciz816. Clin Infect Dis. 2020. PMID: 31545346
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
